Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short–duration response and multifocal intracerebral recurrence preceding radiotherapy

Neurology

Volumn 44, Issue 9, 1994, Pages 1721-1727

  Lachance, D H ^a   Brizel, D M ^a   Gockerman, J P ^a   Halperin, E C ^a   Burger, P C ^a   Boyko, O B ^a   Brown, M T ^a   Schold, S C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; VINCRISTINE;

EID: 0028136259     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.44.9.1721     Document Type: Article

References (40)

1. Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the U.S. Cancer 1988;62:2461-2465.
2. Jellinger K, Radaskiewicz TH, Slowik F. Primary malignant lymphomas of the central nervous system in man. Acta Neu- ropathol (Berl) 1975;suppl 6:95-102.
3. Jellinger K, Slowik F. Primary non-Hodgkin lymphomas of the central nervous system. In: Walker MD, Thomas DGT, eds. Biology of brain tumour. Boston: Martinus Nijhoff, 1986:145–152.
4. Henry JM, Heffner RR, Gillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer 1974;34:1293–1302.
5. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31:1860–1861.
6. Smith WJ, Garson JA, Bourne SP, Kemshead JT, Coakham HB. Immunoglobulin gene rearrangement and antigenic profile confirm B cell origin of primary cerebral lymphoma and indicate a mature phenotype. J Clin Pathol 1988;41: 128–132.
7. Bashir R, Freedman A, Harris N, Bain K, Nadler L, Hochberg F. Immunophenotypic profile of CNS lymphoma: a review of eighteen cases. J Neurooncol 1989;7:249–254.
8. Bashir R, Freedman A, Harris N, Bain K, Nadler L, Hochberg F. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112–2135.
9. Pollack IF, Lunsford LD, Fleckinger JC, Damishek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989;63:939–947.
10. Murray MD, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment in 11 cases and review of the literature. J Neurosurg 1986;65:600–607.
11. Loeffler JS, Ewin TJ, Mauch P, et al. Primary lymphomas ofthe central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 1985;3:490–494.
12. Helle TL, Britt RH, Colby TV. Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford. J Neurosurg 1984;60:94–103.
13. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835–853.
14. Miller TP, Jones SE. Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemother Pharmacol 1980;4:67–70.
15. Miller TP, Grogan TM. Patients with localized non-Hodgkin’s lymphomas provide opportunities for future research. Oncology 1991;5:127–132.
16. Mauch P, Leonard R, Skarin A, et al. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin’s lymphomas. J Clin Oncol 1985;3:1301–1308.
17. Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited- stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989;7:1186–1191.
18. Stewart DJ, Russell N, Dennery J. Cyclophosphamide, Adri- amycin, vincristine and dexamethasone in the treatment of bulky central nervous system lymphoma. In: Walker MD, Thomas DGT, eds. Biology of brain tumour. Boston: Marti- nus Nijhoff, 1986:433–436.
19. Cohen IJ, Vogel R, Matz S, et al. Successful non-neurotoxic therapy (without radiation) of a multi-focal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB). Cancer 1986;57:6–11.
20. Jones SE, Grozea PN, Metz EN, et al. Superiority of Adri- amycin-containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 1979;43:417–425.
21. Cottman CA, Dahlbert S, Jones SE, et al. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin AT, ed. Advances in cancer chemotherapy. New York: Park Row, 1986:71–78.
22. Armitage JO. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin’s lymphoma. Ann Oncol 1991;2 (suppl 1):37–41.
23. Vose JM, Bierman PJ, Weisenburger DD, Armitage JO. The therapy of non-Hodgkin’s lymphomas. In: Armitage JO, ed. Non-Hodgkin’s lymphoma. Hematology/Oncology Clinics of North America, no. 5. Philadelphia: WB Saunders, 1991;5:845–851.
24. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002–1006.
25. Russell S, Rubenstein LJ. Pathology of tumors of the nervous system. 5th ed. Baltimore: Williams & Wilkins, 1989: 596–597.
26. O’Neill BP, O’Fallon J, Jack C, Banks P, Colgan J, Earle J. Patterns of failure in primary central nervous system non- Hodgkin’s lymphoma (PCNSL) [abstract]. Proc Am Soc Clin Oncol 1989;8:87.
27. DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80–86.
28. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635–643.
29. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain-barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580–1590.
30. Hochberg FH, Loeffler JS, Prados M. The therapy of primary brain lymphoma. J Neurooncol 1991;10:191–201.
31. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–1733.
32. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439–449.
33. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 1992;12:103- 110.
34. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157–1160.
35. Offit K, Chaganti RSK. Chromosomal aberrations in non- Hodgkin’s lymphoma. Biologic and clinical correlations. In: Armitage JO, ed. Non-Hodgkin’s lymphoma. Hematology/ Oncology Clinics of North America, no. 5. Philadelphia: WB Saunders, 1991;5:853–869.
36. Dalton WS, Grogan TM, Meltzer PS, et al. Drug resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415–424.
37. DeVita VT, Molloy Hubbard S, Yound RC, Longo DL. The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol 1988;25(suppl 2):2–10.
38. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9–17.
39. Thames HD. On the origin of dose fractionation regimens in radiotherapy. Semin Radiat Oncol 1992;2:3–9.
40. Cox D. Clinical perspectives of recent developments in fractionation. Semin Radiat Oncol 1992;2:10–15.